Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Research & Development (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Research & Development for 16 consecutive years, with $2.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Research & Development fell 14.85% to $2.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $12.6 million, a 2.21% decrease, with the full-year FY2024 number at $12.0 million, down 12.74% from a year prior.
  • Research & Development was $2.4 million for Q3 2025 at Gyre Therapeutics, down from $3.4 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $20.4 million in Q3 2021 to a low of -$50.2 million in Q4 2021.
  • A 5-year average of $2.8 million and a median of $3.4 million in 2024 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: tumbled 96.05% in 2022, then surged 274.72% in 2023.
  • Gyre Therapeutics' Research & Development stood at -$50.2 million in 2021, then surged by 108.59% to $4.3 million in 2022, then rose by 6.01% to $4.6 million in 2023, then decreased by 18.74% to $3.7 million in 2024, then tumbled by 36.34% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Research & Development are $2.4 million (Q3 2025), $3.4 million (Q2 2025), and $3.1 million (Q1 2025).